Strata Critical Medical, Inc.
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
SRTA$6.05+8.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Interim
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss
(in thousands)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net Loss | $(10,516) | $(3,743) | $(8,362) | $(7,236) |
| Other comprehensive income (loss): | ||||
| Foreign currency translation adjustments | — | 2,899 | — | 4,215 |
| Other comprehensive income | — | 2,899 | — | 4,215 |
| Comprehensive loss | $(10,516) | $(844) | $(8,362) | $(3,021) |
Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity
(in thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of April 1, 2026 | 86,521,570 | $7 | $429,121 | $— | $(143,397) | $285,731 |
| Issuance of common stock upon exercise of stock options | 25,000 | — | 3 | — | — | 3 |
| Issuance of common stock upon settlement of restricted stock units | 2,004,366 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 3,706 | — | — | 3,706 |
| Shares withheld related to net share settlement | (826,190) | — | (4,206) | — | — | (4,206) |
| Issuance of common stock in acquisition | 742,060 | — | 4,267 | — | — | 4,267 |
| Non-cash capital contribution | — | — | 333 | — | — | 333 |
| Net loss | — | — | — | — | (10,516) | (10,516) |
| Balance as of June 30, 2026 | 88,466,806 | $7 | $433,224 | $— | $(153,913) | $279,318 |
| Balance as of April 1, 2025 | 80,973,634 | $7 | $407,047 | $3,069 | $(190,391) | $219,732 |
| Issuance of common stock upon exercise of stock options | 43,680 | — | 14 | — | — | 14 |
| Issuance of common stock upon settlement of restricted stock units | 985,270 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 5,349 | — | — | 5,349 |
| Shares withheld related to net share settlement | (306,979) | — | (1,151) | — | — | (1,151) |
| Other comprehensive income | — | — | — | 2,899 | — | 2,899 |
| Net loss | — | — | — | — | (3,743) | (3,743) |
| Balance as of June 30, 2025 | 81,695,605 | $7 | $411,259 | $5,968 | $(194,134) | $223,100 |
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of January 1, 2026 | 86,702,183 | $7 | $424,616 | $— | $(145,551) | $279,072 |
| Issuance of common stock upon exercise of stock options | 311,960 | — | 55 | — | — | 55 |
| Issuance of common stock upon settlement of restricted stock units | 2,340,464 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 8,741 | — | — | 8,741 |
| Shares withheld related to net share settlement | (954,527) | — | (4,788) | — | — | (4,788) |
| Retirement of common stock | (675,334) | — | — | — | — | — |
| Issuance of common stock in acquisition | 742,060 | — | 4,267 | — | — | 4,267 |
| Non-cash capital contribution | — | — | 333 | — | — | 333 |
| Net loss | — | — | — | — | (8,362) | (8,362) |
| Balance as of June 30, 2026 | 88,466,806 | $7 | $433,224 | $— | $(153,913) | $279,318 |
| Balance as of January 1, 2025 | 79,419,028 | $7 | $407,076 | $1,753 | $(186,898) | $221,938 |
| Issuance of common stock upon exercise of stock options | 1,611,847 | — | 74 | — | — | 74 |
| Issuance of common stock upon settlement of restricted stock units | 2,450,677 | — | — | — | — | — |
| Stock-based compensation - restricted stock | — | — | 9,566 | — | — | 9,566 |
| Shares withheld related to net share settlement | (1,785,947) | — | (5,457) | — | — | (5,457) |
| Other comprehensive income | — | — | — | 4,215 | — | 4,215 |
| Net loss | — | — | — | — | (7,236) | (7,236) |
| Balance as of June 30, 2025 | 81,695,605 | $7 | $411,259 | $5,968 | $(194,134) | $223,100 |
See Notes to Unaudited Interim Condensed Consolidated Financial Statements
Unaudited Interim Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(8,362) | $(7,236) |
| Adjustments to reconcile net loss to net cash and restricted cash used in operating activities: | ||
| Change in gain on sale of business | 344 | — |
| Depreciation and amortization | 11,575 | 3,473 |
| Stock-based compensation | 8,741 | 9,566 |
| Change in fair value of warrant liabilities | (1,530) | (2,829) |
| Change in fair value of other assets and liabilities | 2,066 | — |
| Accretion of interest income on held-to-maturity securities | (446) | (1,508) |
| Deferred tax expense (benefit) | (96) | 4 |
| Non-cash capital contribution | 333 | — |
| Other | 126 | 428 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (194) | (1,650) |
| Accounts receivable | (517) | (6,777) |
| Other non-current assets | 77 | 74 |
| Operating right-of-use assets/lease liabilities | 115 | (61) |
| Accounts payable and accrued expenses | (2,645) | 914 |
| Deferred revenue | (15) | 2,292 |
| Net cash provided by/ (used in) operating activities (includes discontinued operations; see Note 5) | 9,572 | (3,310) |
| Cash Flows From Investing Activities: | ||
| Acquisitions, net of cash acquired | (34,823) | — |
| Cash transfer related to sale of business | (290) | — |
| Capitalized software development costs | (616) | (961) |
| Purchase of property and equipment, net of proceeds from disposal | (7,669) | (4,849) |
| Purchase of held-to-maturity investments | (6,254) | (96,403) |
| Proceeds from maturities of held-to-maturity investments | 30,500 | 151,300 |
| Net cash (used in) / provided by investing activities (includes discontinued operations; see Note 5) | (19,152) | 49,087 |
| Cash Flows From Financing Activities: | ||
| Proceeds from the exercise of common stock options | 55 | 74 |
| Taxes paid related to net share settlement of equity awards | (4,788) | (5,457) |
| Payments for debt issuance costs | (338) | — |
| Net cash used in financing activities (includes discontinued operations; see Note 5) | (5,071) | (5,383) |
| Effect of foreign exchange rate changes on cash balances | — | 277 |
| Net (decrease) / increase in cash and cash equivalents and restricted cash | (14,651) | 40,671 |
| Cash and cash equivalents and restricted cash - beginning | 31,232 | 19,647 |
| Cash and cash equivalents and restricted cash - ending | $16,581 | $60,318 |
| Reconciliation to consolidated balance sheets (includes discontinued operations; see Note 5) | ||
| Cash and cash equivalents | $16,317 | $58,754 |
| Restricted cash | 264 | 1,564 |
| Total cash and cash equivalents and restricted cash | $16,581 | $60,318 |
| Supplemental cash flow information | ||
| Cash paid for: | ||
| Income Taxes paid | $93 | $23 |
| Non-cash investing and financing activities: | ||
| New leases under ASC 842 entered into during the period | $1,317 | $1,200 |
| Common stock issued for acquisition | 4,267 | — |
| Consideration payable in other current liabilities | 2,950 | — |
| Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 59 | 234 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.